Every August, World Cancer Support Month reminds us that no one faces cancer alone. It reaches beyond the person diagnosed to touch families, friends, caregivers, and whole communities. Much of the month rightly focuses on the support people need during treatment: the rides to appointments, the counseling, the meals dropped off, the hands held in waiting rooms.
At PRECEDE, we want to widen that conversation. When it comes to pancreatic cancer, some of the most meaningful support begins well before anyone is ever diagnosed.
The weight of not knowing
Pancreatic cancer is one of the hardest cancers to catch early. It tends to develop quietly, with few clear symptoms, until it has already advanced. That reality shapes daily life for people who carry a higher risk, whether through a strong family history, an inherited genetic change, or another known risk factor. Many of them live with a quiet, ongoing worry, wondering whether the disease that affected a parent or a sibling might one day affect them too.
That worry is its own kind of burden. And it deserves its own kind of support.
A different kind of support
This is the heart of what PRECEDE does. The PRECEDE Consortium brings together roughly 65 academic medical centers across 12 countries to enroll and monitor people at high risk for pancreatic cancer. For the individuals and families in the program, surveillance is more than a medical protocol. It is reassurance. It is the knowledge that experienced clinicians are watching closely, that any changes will be caught as early as possible, and that no one is navigating their risk in the dark.
Support, in this sense, looks like being seen. It looks like a global community of researchers, physicians, and families all working toward the same goal, so that a person at risk never has to carry that uncertainty by themselves.
Turning research into hope
PRECEDE was founded on the belief that early detection can change the course of this disease. Today, only about 13 percent of people diagnosed with pancreatic cancer are alive five years later. We exist to change that number. Our goal is to raise the five-year survival rate to 50 percent, and early detection is how we intend to get there.
Every person enrolled, every biospecimen studied, and every insight shared across the consortium moves the entire field a step closer to a future where a pancreatic cancer diagnosis is far less frightening than it is today. For high-risk families, that progress is not abstract. It is a reason to keep hoping.
What support can look like this month
World Cancer Support Month is a chance to think about what support really means. It can mean checking in on someone you love who is living with cancer or caring for someone who is. It can mean learning your own family history and talking with a doctor about your risk. And it can mean helping fund the research that gives high-risk families something powerful to hold onto: hope, backed by science.
If you would like to stand with the families we serve, your support helps make earlier detection possible for the people who need it most.
